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Pharmacokinetic research at the host-microbe interface has been primarily directed towards effects on 
drug metabolism, with fewer investigations considering the absorption process. We previously 
demonstrated that the transcriptional expression of genes encoding intestinal transporters involved in 
lipid translocation are altered in germ-free and conventionalized mice possessing distinct bile acid 
signatures. It was consequently hypothesized that microbial bile acid metabolism, that is the 
deconjugation and dehydroxylation of the bile acid steroid nucleus by gut bacteria, may impact upon 
drug transporter expression and/or activity and potentially alter drug disposition. 
Using a panel of three human intestinal cell lines (Caco-2, T84 and HT-29), that differ in basal 
transporter expression level, bile acid conjugation- and hydroxylation- status was shown to influence 
the transcription of genes encoding several major influx and efflux transporter proteins. We further 
investigated if these effects on transporter mRNA would translate to altered drug disposition and 
activity. The results demonstrated that the conjugation and hydroxylation status of the bile acid steroid 
nucleus can influence the cellular response to multidrug resistance (MDR) substrates, a finding that did 
not directly correlate with directionality of gene or protein expression. In particular, we noted that the 
cytotoxicity of cyclosporin A was significantly augmented in the presence of the unconjugated bile 
acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) in P-gp positive cell lines, as 
compared to their taurine/glycine-conjugated counterparts, implicating P-gp in the molecular response. 
Overall this work identifies a novel mechanism by which gut microbial metabolites may influence drug 
accumulation and suggests a potential role for the microbial bile acid-deconjugating enzyme bile salt 
hydrolase (BSH) in ameliorating multidrug resistance through the generation of bile acid species with 
the capacity to access and inhibit P-gp ATPase. The physicochemical property of nonionization is 
suggested to underpin the preferential ability of unconjugated bile acids to attenuate the efflux of P-gp 
substrates and to sensitize tumorigenic cells to cytotoxic therapeutics in vitro. This work provides new 
impetus to investigate whether perturbation of the gut microbiota, and thereby the bile acid component 
of the intestinal metabolome, could alter drug pharmacokinetics in vivo. These findings may 
additionally contribute to the development of less toxic P-gp modulators, which could overcome MDR.
Keywords: Microbiota; bile acid metabolism; pharmacokinetics; drug absorption; multidrug 
resistance; drug transporter
Abbreviations: ABC, ATP-binding cassette; ADP, adenosine diphosphate; ATP, adenosine 
triphosphate; BCRP, Breast Cancer Resistance Protein; Caco-2, human colorectal adenocarcinoma cell 
line; CA, cholic acid; CAR, constitutive androstane receptor; CDCA, chenodeoxycholic acid; CsA, 
cyclosporine A; CYP, cytochrome P450; DCA, deoxycholic acid; FXR, farnesoid X receptor; LCA, 
lithocholic acid; MRP, Multidrug Resistance Protein; mRNA, messenger RNA; OCT1, Organic Cation 
Transporter 1; PepT1, Peptide Transporter 1; P-gp, P-glycoprotein; PWSDs, poorly water-soluble 
drugs; PXR, pregnane X receptor; SLC, solute carrier transporters; TCDCA, taurochenodeoxycholic 
acid, TDCA, taurodeoxycholic acid;
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The human gastrointestinal tract can be viewed as a microbial ecosystem, harbouring several trillion 
microbial cells with varied functional repertoires. These collections of symbiotic bacteria have been 
widely reported to influence drug metabolism and thereby modulate clinical outcome.[1] Comparatively 
fewer studies have, however, investigated possible effects on the drug absorption process. The 
combination of an ‘unstirred’ water layer, tight junctions and an epithelial cell membrane expressing 
efflux proteins can in some instances severely limit drug transport across the intestinal barrier. We 
previously established that gut microbial bile acid metabolism can influence the solubilization capacity 
of simulated intestinal fluids and consequently the solubility of poorly water-soluble drugs (PWSDs).[2] 
Bile acids, at the millimolar micelle-invoking concentrations employed in this previous study, have 
been extensively investigated as emulsification and permeation enhancers with demonstrable roles in 
regulating lipophilic drug absorption.[3, 4] However, there remains a paucity of data examining the 
effects of bile acids on drug transport at micromolar signalling concentrations as endobiotic ligands for 
nuclear receptors or their influence on other cellular properties that may impact drug transport.[5] 
The primary bile acids in humans, cholic acid (CA) and chenodeoxycholic acid (CDCA), are 
synthesized in hepatocytes from cholesterol.[6] Subsequent to their biosynthesis, these primary bile 
acids are conjugated to either taurine or glycine, at a respective ratio of approximately 1:3, via an N-
acyl amide bond. Amidation facilitates protonation at physiological pH and hence conjugated bile acids 
exist in an ionized form and are more correctly described as salts. Conjugated bile salts are stored and 
concentrated in the gallbladder for the interprandial period. Postprandially, the gallbladder is stimulated 
by cholecystokinin and bile salts enter the intestine wherein biotransformation by commensal bacteria 
occurs. Firstly, the microbial enzyme bile salt hydrolase (BSH) catalyses the hydrolysis of the 
taurine/glycine appendage liberating the free, unconjugated bile acid. Regenerated unconjugated CA 
and CDCA are then eligible for 7α-dehydroxylation, mediated by microbial 7α-dehydroxylase, yielding 
the secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA), respectively (Figure 1). 
All of these deconjugated and dehydroxylated bile acid species can be recirculated to the liver via the 
portal blood where taurine/glycine reconjugation occurs. Although the genesis of the bile acid pool is 
synthesis by the host, its composition and physicochemical signature is thus significantly influenced by 
the microbiome. 
In recent years, the role of endobiotic- (including bile acid) inducible nuclear receptors in regulating 
transporter expression has been uncovered.[7] These nuclear receptors display bile acid-specific 
sensitivities, such that subtle changes in local or systemic bile acid profiles could impact host 
physiology.[8] Previous studies within our group revealed that microbial re-colonization of germ-free 
mice significantly influences transcription of genes encoding intestinal transporters involved in lipid[9] 
and drug uptake (Figure 1, Supporting Information). As the bile acid pool composition of 
conventionalized mice is more chemically diverse than that of their germ-free counterparts,[10] we 
hypothesized that gut microbiota-mediated bile acid metabolism may impact upon the expression of 
drug transporters. Drug disposition is most often influenced by two superfamilies, the ATP-binding 
cassette (ABC) and solute carrier (SLC) transporters,[11] we thus focussed our efforts on elucidating 
the effect of bile acid deconjugation and dehydroxylation on the transcription and activity of 6 clinically 
relevant members (Figure 1, Supplemental Information, and Table 1).  
Tumorigenic multidrug resistance has been associated with the overexpression of efflux transporter 
proteins of the ABC superfamily, including P-glycoprotein (P-gp, ABCB1) and Breast Cancer 
Resistance Protein (BCRP, ABCG2).[12] These transport proteins are also highly abundant at the apical 
membrane of the enterocytes and by returning a proportion of absorbed drug to the lumen, often pose a 
barrier to the uptake of susceptible substrates.[11, 13] Down-regulation, or inhibition of these multidrug 
resistance proteins by substrate competition, ATP depletion, or membrane perturbation may, therefore, 
augment intestinal absorption, as well as induce tumorigenic chemo-sensitivity.[14] Several lipophilic 
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drugs, such as verapamil, have proved useful as reversal agents in vitro and in preclinical animal models, 
[15, 16] however, their clinical applicability is likely to be limited by innate pharmacodynamic effects. 
Therefore, it is of interest to explore the endogenous factors that might influence the action of these 
transporters, and to identify reversing agents of low toxicity. 
Cyclosporine A (CsA) is an immunosuppressive calcineurin inhibitor, which is typically prescribed in 
the setting of organ transplantation for the prophylaxis or treatment of allograft rejection.[17] Its clinical 
use is frequently challenged by highly variable pharmacokinetics, necessitating patient-specific dosage 
adjustments. In addition to CsA’s susceptibility to metabolism by CYP3A4[18], several reports indicate 
that interpatient discrepancies in bioavailability can be partially ascribed to alterations in the intestinal 
expression of P-gp.[19, 20] In light of its reported curtailing effects on the growth of colon cancer cell 
lines,[21] CsA was selected for use in this study as a clinically relevant P-gp substrate with the potential 
to induce cytotoxicity. This latter characteristic affords the opportunity to assess variations in 
transporter functioning as changes in cellular toxicity. Similarly, SN-38, the active metabolite of the 
antineoplastic drug irinotecan, was chosen as a model substrate to evaluate the impact of bile acid 
conjugation and hydroxylation status on the activity of BCRP.[22]
Overall, this paper provides insight into the role of bile acid deconjugation and dehydroxylation 
(governed in vivo by the gut microbiota) in altering the multidrug resistant phenotype of Caco-2 and 
T84 cell lines, in vitro models of both the intestinal barrier and a tumorigenic colon. Firstly we examined 
the effect of conjugated/deconjugated and trihydroxy/dihydroxy bile acids on the messenger RNA 
(mRNA) transcripts of common enterocytic influx and efflux transporters. Secondly, we investigated 
whether these bile acid alterations to transporter mRNA could translate to altered drug disposition and 
activity using an in vitro cytotoxicity screen. In the absence of a correlation between altered drug 
activity and the directionality of gene/protein expression and considering reports of the non-
transcriptional resistance reversing effects of surfactants,[23] other possible mechanisms by which bile 
acids could affect the absorptive potential of intestinal epithelial were investigated. As the composition 
of gut microbial communities, and thereby their metabolites, can vary greatly between individuals,[24] 
this work seeks to enhance the knowledge base of novel mechanisms by which the gut microbiome can 
contribute to pharmacokinetic variability. 
Figure 1. A schematic overview of microbial bile acid metabolism. Primary bile salts synthesized and 
glycine/taurine-conjugated by the host are released into the duodenum, functioning as physiological surfactants 
to aid the digestive process. Within the intestinal environment, these conjugated bile salts are substrates for 
microbial biotransformation, specifically glycine/taurine-deconjugation (mediated by the microbial enzyme bile 
salt hydrolase) and 7α-dehydroxylation (mediated by the microbial enzyme 7α-dehydroxylase).  As a consequence 
of enterohepatic circulation, the human bile acid pool is comprised of free and conjugated forms of both host- 
(primary) and microbe- (secondary) derived bile acids. 
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2. Materials and Methods
Materials
Cyclosporine A (CsA) from Tolypocladium inflatum (purity ≥ 95 %), SN-38 (purity ≥ 98 %), verapamil 
hydrochloride (≥ 99 %), rhodamine 6G, dimethyl sulfoxide (DMSO, Hybri-Max, sterile-filtered, 
BioReagent, purity ≥ 99.7%), sodium taurocholate hydrate (≥ 95 %), cholic acid sodium salt hydrate (≥ 
96%), sodium taurodeoxycholic acid hydrate (≥ 95 %), deoxycholic acid (≥ 99 %), sodium 
taurochenodeoxycholate (≥ 98 %), sodium chenodeoxycholate (≥ 97 %), thiazolyl blue tetrazolium 
bromide (MTT), Costar 3412 polycarbonate membrane cell culture transwell inserts (24 mm diameter, 
0.4 µm pore size), Dulbecco’s modified Eagle medium (DMEM), MEM non-essential amino acid 
solution (100 x), foetal bovine serum (FBS), penicillin-streptomycin, Ham’s Nutrient Mixture F-12, 
phosphate buffered saline, T-175 flasks, tissue culture treated plates and other tissue culture reagents 
were sourced from Sigma-Aldrich, Ireland. RNeasy mini-kit was obtained from Qiagen Ltd., Ireland. 
TURBO DNA-free™ Kit was sourced from ThermoFisher Scientific, Ireland. Transcriptor reverse 
transcriptase and Universal Probe Library probes were procured from Roche LifeScience, Ireland.  
Primer “random”, Protector RNase inhibitor and PCR Nucleotide Mix were purchased from Sigma-
Aldrich, Ireland. SensiFAST™ Probe No-ROX Kit was sourced through MSC Ltd., Ireland. Primers 
were purchased from Eurofins Scientific, Ireland. Gels and buffers used for western blotting were 
sourced from BioSciences, Ireland. Anti-Sodium Potassium ATPase antibody, anti-P-glycoprotein 
antibody and anti-BCRP antibody were purchased from Abcam, Cambridge, UK. CellTiter Glo and P-
gp-Glo assay systems were sourced through Promega, Ireland. 
Cell line and culture 
Caco-2 human epithelial colorectal adenocarcinoma cells, maintained by APC Microbiome Ireland and 
the School of Pharmacy cell culture collections and originally procured from the American Type 
Culture Collection (Rockville), were used at passage numbers 36-55 for the work described herein. 
Caco-2 cells were maintained in DMEM supplemented with 10 % (v/v) FBS, 1 % (v/v) non-essential 
amino acids and 100 U/ml penicillin and 100 µg/ml streptomycin. T84 human colon carcinoma (lung 
metastasis) cells, sourced from Sigma-Aldrich and maintained by APC Microbiome Ireland cell culture 
collection, were used as passage numbers 5-18. T84 cells were maintained in DMEM:F-12 with 10 % 
(v/v) FBS and 100 U/ml penicillin and 100 µg/ml streptomycin. HT-29 human colon adenocarcinoma 
cells, maintained by APC Microbiome Ireland, were used at passage numbers 13-25 for the work 
described herein. HT-29 cells were maintained in McCoy’s 5A supplemented with 10 % (v/v) FBS and 
100 U/ml penicillin and 100 µg/ml streptomycin. Cell lines were routinely grown in 175 cm2 tissue 
culture flasks and passaged twice weekly at a dilution of 1:5 and incubated at 37 °C in a humidified 
chamber containing 5 % CO2 and 95 % air.
RNA extraction, cDNA synthesis and quantitative PCR
Caco-2, T84 or HT-29 cells were plated in 6 well plates at a density of 50,000 cells/cm2 in supplemented 
growth media (2.5 mL/well). 24 h later, cells were treated with 100 µM (Caco-2 and HT-29) or 50 µM 
(T84) test bile acids or an equivalent volume of DMSO (vehicle control) in DMEM:F-12 (Caco-2 and 
T84) or serum-free DMEM (HT-29). Following 24 h incubation, treatment media was aspirated, the 
cells were washed once with phosphate buffered saline (PBS) and RNA was isolated using the RNeasy 
mini-kit (Qiagen) according to the manufacturer’s instructions. The quality and quantity of the purified 
(and TURBO DNase-treated) RNA was analysed using a NanoDrop Spectrophotometer. The samples 
were stored at – 80 °C pending the next steps outlined below.
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cDNA synthesis was performed using 300-500 ng total RNA isolated from cells and mastermix 
consisting of a blend of 5 X transcriptor buffer (Roche), random primer (Roche), transcriptor reverse 
transcriptase (RT) enzyme (Roche), protector RNase inhibitor (Roche) and dNTP (Roche) in a total 
volume of 20 µL. cDNA was synthesized using a thermal cycler according to the following protocol 
steps: 1) primer annealing at 25 °C for 10 min, 2) cDNA synthesis at 55 °C for 30 min, 3) RT heat 
inactivation at 85 °C for 5 min, followed by cooling to 4 °C. The reaction mixture was then diluted to 
100 µL with nuclease-free H2O and stored at - 20 °C until analysis.
Specific primers for each gene (designed using the Universal Probe Library (Roche) and listed in Table 
1) were used for quantitative PCR (qPCR) using a LightCycler® 480 Real-Time PCR system (Roche, 
Dublin, Ireland). A cycle consisted of: 10 seconds at 95 °C, 45 seconds at 60 °C, 1 second at 70 °C, and 
repeated for a total of 55 cycles. The expression of target genes in each sample was evaluated using the 
crossing-threshold value (Ct). The results were normalized to the β actin gene and relative mRNA 
expression was computed based on the comparative cycle threshold method (  [25]2 ―∆∆𝐶𝑡).
Cell viability assay 
Cell viability was assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega), which 
enables the number of viable cells in culture to be determined based on ATP quantification. Cells were 
exposed to conjugated/deconjugated or primary/secondary bile acids in the absence and presence of 
model efflux substrates (such as SN-38 or CsA) to investigate the impact of microbe-mediated bile acid 
metabolism on cell viability and drug response. 
Cells were plated at a density of 1.6 X 104 cells per well in 96-well plates and cultured for 24 h in 100 
µL supplemented growth media. Following growth media aspiration, the cells were then exposed to 
serum-free DMEM:F-12 (Caco-2 and T84) or serum-free McCoy’s (HT-29) media containing test bile 
acids and/or SN-38 or CsA, at concentrations indicated in the figures. All test substances were dissolved 
in DMSO at concentrations of 100 mM and 10 mM for bile acids and SN-38/CsA, respectively, and 
subsequently diluted with DMEM:F-12 (Caco-2 and T84) or serum-free McCoy’s culture medium. 
Culture medium containing 0.05-0.2% DMSO, dependent upon the concentration or combination of 
test substances, served as negative controls. Subsequent to a 24 h treatment period, the plate was 
measured for luminescence using a BioTek Synergy 2 multi-mode microplate reader (Mason 
Technology, Ireland). 
A tetrazolium-based MTT colorimetric assay was employed to verify the non-cytotoxicity of 100 µM 
unconjugated bile acids. Similar to the CellTiter Glo assay, Caco-2 cells were seeded at a density of 1.6 
X 104 cells per well in 96-well plates in supplemented DMEM growth media. 24 h later, the media was 
removed and cells were treated with 100 µM test bile acids or an equivalent volume of DMSO vehicle 
(control) in DMEM:F-12. 3 h prior to the completion of the 24 h treatment period, 20 µL of a 5 mg/ml 
solution of MTT (3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) in 
phosphate buffered saline (PBS) was added to each well and the cells were further incubated for 3 h. 
The media was subsequently removed and the cells were washed twice with PBS. Solubilization of the 
formazan crystals was achieved by the addition of 200 µL DMSO to each well. Absorbance (OD) was 
measured with background subtraction at 570 nm using a VICTOR2™ 1420 multilabel counter (Wallac 
Oy, Turku, Finland). Viability was calculated in comparison to vehicle-treated cells, representing 100 
% viability. All viability data is presented as the mean ± SEM of 3-4 independent experiments 
performed in triplicate. 
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Cells were treated with either 100 µM (Caco-2 and HT-29) or 50 µM (T84) TDCA, DCA, or DMSO 
vehicle control for 24 h as outlined above for RNA isolation. Following treatment, the growth media 
was aspirated and cells were rinsed with cold PBS. Cells were subsequently lysed in RIPA buffer (50 
mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulphate containing 1 X HALT protease and phosphatase inhibitors). Culture plates containing lysis 
buffer were left on ice for 10 min, after which lysate was collected using a cell scraper into pre-chilled 
Eppendorf tubes. Lysates were kept on ice for an additional 20 min. To remove debris, lysates were 
centrifuged at 14000 rpm for 15 min at 4 °C and the supernatants were collected. Total protein content 
was determined according to the BCA assay (Pierce). Proteins in the samples used for BCRP 
immunoblotting were denatured by boiling for 10 min. Samples used for Na+/K+-ATPase (loading 
control) and P-gp immunoblotting were not denatured. Total protein (13.5 µg) was resolved on 3-8% 
Tris-Acetate gels (NuPAGE) using NuPAGE Tris-Acetate SDS running buffer. 500 µL Bolt 
Antioxidant was added to the cathode chamber. Following electrophoresis (150 V until adequately 
resolved), proteins were transferred onto PVDF (0.45 µm) membranes (30 V for 90 min). Following 
transfer, membranes were blocked with 5% w/v non-fat dry milk in PBS-0.1% v/v Tween-20 for 1 h at 
room temperature.  The membranes were then incubated with gentle shaking at 4 °C overnight with the 
relevant primary antibody in 15 mL PBS containing 1% w/v bovine serum albumin and 0.1% v/v 
Tween-20. Primary antibodies were used at a dilution of 1:10000, 1:1000 and 1:1000 for Na+/K+-
ATPase, BCRP and P-gp, respectively. The following day, membranes were incubated for 1 h at room 
temperature with goat anti-rabbit HRPase-conjugated secondary antibodies at a 1:10000 dilution in 5% 
w/v non-fat dry milk in PBS-0.1% v/v Tween-20. Bands were visualized using the Advansta 
WesternBright Quantum kit. Protein expression levels were quantified using NIH Image J software, 
with the relative quantity of BCRP and P-gp protein expression calculated with respect to Na+/K+-
ATPase.
Rhodamine 6G accumulation assay
The P-gp activity of conjugated (TCDCA and TDCA) and deconjugated (CDCA and DCA) bile acids  
was assessed by measuring the intracellular accumulation of rhodamine 6G (Rho 6G) in Caco-2 and T-
84 cells with or without the co-presence of the test bile acid. Briefly, cells were incubated with 5 µM 
(Caco-2) or 2.5 µM (T84) Rho 6G (in DMEM:F-12) for 3 hr with/without 100 µM test bile acid. 
Following the incubation period, the cells were washed twice with serum-free culture media and then 
lysed using 100 µL 1% (w/v) Triton X-100 (Sigma-Aldrich, Ireland) at room temperature. Intracellular 
levels of Rho 6G were quantified spectroflourometrically using a VICTOR2™ 1420 multilabel counter 
(Wallac Oy, Turku, Finland) with excitation (λEX) and emission (λEM) wavelengths set at 485 nm and 
615 nm, respectively. Data was expressed as the percentage accumulation of Rho 6G in test cells relative 
to accumulation in untreated control cells, arbitrarily set at 100%. Increased intracellular accumulation 
of Rho 6G corresponds to reduced efflux activity. 
In order to gain insight into the mechanism by which bile acids may modulate the increased cellular 
uptake of Rho 6G, accumulation assays were performed as outlined above at 4 °C, 21 °C and 37 °C. 
Experimental data is expressed as the mean ± SEM of four independent experiments (with n = 6 
replicates per experiment). 
Rhodamine 6G apparent permeability assay 
Bidirectional permeability assessments were performed using polycarbonate membrane cell culture 
transwell inserts (24 mm diameter, 0.4 µm pore size). Caco-2 cells were seeded at a density of 63,000 
cells/cm2 in supplemented DMEM and allowed to differentiate over a period of 21-23 days until 
transepithelial electrical resistance (TEER) reached ≥ 350 ohms. TEER values were measured 
periodically at the initiation of cell culture media changes (alternate days), as well as before and after 
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testing using an EVOM-Epithelial Voltohmmeter (World Precision Instruments, USA). During 
maintenance and testing, apical and basolateral chamber volumes were 1.5 ml and 2.6 ml, respectively. 
All transport experiments were carried out in triplicate. On experimental days, the mean TEER value 
was 408 ± 12 ohms following change to test media (DMEM:F-12). For test conditions, 100 µM test bile 
acids (TDCA/DCA) or verapamil (positive control) were added to both sides of the monolayer 1 h prior 
to initiation of the transport assay. Subsequent to this 1 h pre-incubation period, 5 µM Rho 6G (from a 
5 mM DMSO stock) was added to the donor chamber and drug transport to the receiver chamber was 
analysed over 3 h at 37 °C. 100 µL samples were withdraw from the receiver chamber at 30, 60, 90, 
120, 150 and 180 minutes and replaced with fresh media (containing test bile acid or verapamil, as 
appropriate). A 100 µL sample was also withdrawn from the donor chamber at the beginning (which 
was replenished with an equivolume of 5 µM Rho 6G-containing media) to confirm the initial donor 
concentration.
Rho 6G concentrations were determined on the basis of a standard curve with treatment solutions of 
known molarity (R2 ≥ 0.99). The cumulative amount of Rho 6G transported to the receiver chamber 
was calculated taking into consideration previously removed sample volumes. 
The apparent permeability coefficient (Papp, cm/s) of Rho 6G was calculated according to;
 𝑃𝑎𝑝𝑝 =  
𝑉𝐷
[𝐴 ×  𝑀𝐷] ×  
∆𝑀𝑅   
∆𝑡
Where  is the donor chamber volume (cm3);  is the surface area of monolayer (4.67  cm2);  is the initial 𝑉𝐷 𝐴 𝑀𝐷
concentration of drug in the donor chamber (mol); and   is the change in receiver drug concentration over 
∆𝑀𝑅   
∆𝑡
time (mol/s).  
In an effort to assess the impact of microbial bile acid metabolism on Rho 6G efflux, efflux ratios under 
the various test conditions were calculated by dividing the Papp, B→A by Papp, A→B. For B → A transport, 
the basolateral chamber is the donor chamber and the apical chamber is the receiver chamber. 
Conversely, for A → B transport, the apical chamber is the donor compartment and the basolateral 
chamber is the receiver compartment. 
Data is expressed as the mean ± SD of 2 independent experiments performed in triplicate. 
P-gp ATPase activity assay
The effect of test bile acids, as well as confirmation of P-gp substrate activity, on P-gp ATPase was 
examined using the P-gp-Glo assay system (Promega) according to the manufacturer’s protocol with 
slight modification (a 3 h incubation period was utilized due to the low basal ATPase activity of the 
P-gp membranes). All data is presented as the mean ± SD (n =3). 
Statistical analysis
A two-tailed, independent samples t-test, assuming normal distribution and equal variance, was used to 
assess the statistical significance for two-sample comparison. A P value < 0.05 was regarded to be 
statistically significant.  All statistical analyses were conducted using GraphPad Prism 5 (San Diego, 
California). 
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Table 1. Primers for quantitative PCR analysis. Nucleotide sequences are presented for primer pairs of the 
genes of interest.
Transporter name Gene name Sequence (5’-3’)
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3.1 Impact of bile acid conjugation and hydroxylation state on intestinal drug transporter 
expression
In the liver, bile acid-dependent activation of FXR is known to induce the expression of transporters 
that function to extrude bile salts, cholesterol and phospholipids into the bile canaliculi.[26] While there 
is some evidence that bile acids can affect the expression of various ABC transporters in non-hepatic 
tissues [27, 28], to our knowledge, the effect of microbially biotransformed bile acids on enterocytic 
drug transporters and drug activity has not yet been considered. The impact of microbial BSH and 7α-
dehydroxylase activity on the expression of six intestinal transporters commonly implicated in altered 
drug disposition in vivo was hence simulated in three intestinal cell lines with conjugated/deconjugated 
(Table 2) or primary/secondary (Table 3) bile acids. The bile acid concentrations employed were 
determined to be non-cytotoxic to the cell lines (Figure 2, Supporting Information) and fall within the 
range of that expected in the fecal water of healthy individuals following the consumption of a normal 
diet. [29]
In general, unconjugated DCA and CDCA increased, relative to vehicle control and their conjugated 
counterparts, the expression of genes encoding enterocytic drug transporters (Table 2). The inferred 
impact of microbial bile acid deconjugation on the expression of ABCB1 (P-gp) and ABCG2 (BCRP), 
however, differed from this generalizable trend across the three cell lines. Comparative expression 
profiles of CA- and DCA- treated cells were consistent with the findings of bile acid deconjugation, 
that is, the increased hydrophobicity of the steroidal nucleus of DCA was associated with increased 
expression of intestinal drug transporter mRNA (Table 3) in the three cell lines. Deviations from this 
general trend were again noted for ABCB1 (P-gp) and ABCG2 (BCRP) mRNA (Table 3). 
In an effort to investigate if unconjugated, dihydroxy bile acids were likely to upregulate drug 
transporter mRNA through stimulation of FXR, effects on the expression of FGF19, a well-known 
FXR-regulated gene, were assessed. In general, unconjugated DCA and CDCA upregulated FGF19 
mRNA (Table 2, Supporting Information) in a manner similar to that observed for ABCC2 and ABCC3, 
which are purportedly regulated by FXR. [30] 
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Cell line Gene name Relative mRNA expression following bile acid treatment
TCDCA CDCA TDCA DCA
ABCB1
Caco-2a 0.55 ± 0.06 * 1.1 ± 0.14 0.96 ± 0.07 0.99 ± 0.05
T84b 1.07 ± 0.20 0.76 ± 0.02 *** 1.05 ± 0.10 0.9 ± 0.05
HT-29a 0.87 ± 0.10 3.19 ± 0.63 * 1.52 ± 0.32 2.47 ± 0.25 **
ABCG2
Caco-2a 1.8 ± 0.13 *** 4.7 ± 0.99 ** 1.09 ± 0.11 3.69 ± 0.90 *
T84b 0.91 ± 0.07 0.79 ± 0.05 ** 1.16 ± 0.10 0.81 ± 0.02 ***
HT-29a 1.04 ± 0.52 0.66 ± 0.33 ** 1.13 ± 0.57 1.31 ± 0.66
ABCC2
Caco-2a 0.83 ± 0.09 2.29 ± 0.28 ** 0.82 ± 0.13 1.96 ± 0.43
T84b 1.06 ± 0.07 2.21 ± 0.24 ** 1.05 ± 0.07 2.25 ± 0.16 **
HT-29a 1.08 ± 0.05 6.55 ± 1.72 * 0.99 ± 0.11 8.99 ± 1.84 **
ABCC3
Caco-2a 0.59 ± 0.08 ** 2.75 ± 0.33 ** 0.93 ± 0.07 1.69 ± 0.24 *
T84b 0.99 ± 0.04 2.32 ± 0.28 ** 1.03 ± 0.09 2.35 ± 0.16 **
HT-29a 1.13 ± 0.03 ** 2.72 ± 0.29 ** 1.08 ± 0.07 3.22 ± 0.27 ***
SLC15A1
Caco-2a 0.96 ± 0.16 2.43 ± 0.16 *** 0.93 ± 0.02 ** 2.17 ± 0.21 **
T84b 1.05 ± 0.05 2.16 ± 0.16 ** 1.06 ± 0.04 2.42 ± 0.12 ***
HT-29a ND ND ND ND
SLC22A1
Caco-2a 0.98 ± 0.06 2.23 ± 0.21 ** 1.09 ± 0.22 1.18 ± 0.12
T84b 0.81 ± 0.08 1.37 ± 0.07 * 1.01 ± 0.26 1.52 ± 0.12 **
HT-29a 1.05 ± 0.18 2.17 ± 0.53 0.9 ± 0.09 2.98 ± 0.47 **
Table 2. Fold change in major intestinal drug efflux and uptake transporter gene expression (relative to vehicle 
control), examining the influence of bile acid conjugation status (governed by microbial BSH activity in vivo) on 
such transporters. Quantitative PCR was performed using total RNA extracted from 24 h 100 µMa or 50 µMb bile 
acid- or vehicle-treated cells. Gene expression was normalized to β actin. Data is expressed as the mean ± SEM 
of 4 independent experiments performed in duplicate for the Caco-2 and HT-29 cell lines and as the mean ± SEM 
of 3 independent experiments performed in triplicate for the T84 cell line. Asterisks denote a statistically 
significant difference in mRNA expression compared to vehicle controls. ND = not detected. Δ Ct values 
providing an indication of the basal expression level of each gene (relative to β-actin) are provided in the 
Supporting Information (Table 1).
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Cell line Gene name Relative mRNA expression following bile acid treatment
  CA DCA
ABCB1
Caco-2a  0.83 ± 0.07 1.48 ± 0.30
T84b  0.93 ± 0.04 0.9 ± 0.05
HT-29a  1.65 ± 0.33 2.47 ± 0.25 **
ABCG2
Caco-2a  1.15 ± 0.08 4.34 ± 0.25 ***
T84b  0.97 ± 0.06 0.81 ± 0.02 ***
HT-29a  1.26 ± 0.21 1.31 ± 0.15
ABCC2
Caco-2a  1.09 ± 0.11 2.47 ± 0.38 **
T84b  0.99 ± 0.04 2.25 ± 0.16 **
HT-29a  1 ± 0.09 8.99 ± 1.84 **
ABCC3
Caco-2a  0.99 ± 0.02 1.98 ± 0.30 *
T84b  1 ± 0.05 2.35 ± 0.16 **
HT-29a  1.11 ± 0.10 3.22 ± 0.27 ***
SLC15A1
Caco-2a  1 ± 0.04 2.41 ± 0.25 **
T84b  1.1 ± 0.11 2.42 ± 0.12 ***
HT-29a  ND ND
SLC22A1
Caco-2a  1.12 ± 0.23 3.81 ± 2.17
T84b  1.05 ± 0.10 1.52 ± 0.12 *
HT-29a  1.1 ± 0.12 2.98 ± 0.47 **
Table 3. Fold change in major intestinal drug efflux and uptake transporter gene expression (relative to vehicle 
control), examining the influence of bile acid hydroxylation status (governed by microbial 7α-dehydroxylase 
activity in vivo) on such transporters. Quantitative PCR was performed using total RNA extracted from 24 h 100 
µMa or 50 µMb bile acid- or vehicle-treated cells. Gene expression was normalized to β actin. Data is expressed 
as the mean ± SEM of 4 independent experiments performed in duplicate for the Caco-2 and HT-29 cell lines and 
as the mean ± SEM of 3 independent experiments performed in triplicate for the T84 cell line. Asterisks denote a 
statistically significant difference in mRNA expression compared to vehicle controls. ND = not detected. Δ Ct 
values providing an indication of the basal expression level of each gene (relative to β-actin) are provided in the 
Supporting Information (Table 1). 
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3.2 Impact of bile acid deconjugation on the cellular response to therapeutics 
To explore whether the observed alterations in intestinal drug transporter expression would translate to 
altered drug disposition and activity in vitro, initial work was undertaken in the Caco-2 cell line. DCA 
was determined to augment the cytotoxicity of CsA and SN-38, known substrates for P-gp- and BCRP- 
mediated efflux, respectively (Figure 2 (a), Figure 3 (a)). This ability of DCA to enhance the 
cytotoxicity of these MDR substrates did not correlate with the directionality of ABCB1 (P-gp) or 
ABCG2 (BCRP) expression (Table 2). Given the well investigated role of P-gp and BCRP in limiting 
the intestinal absorption of many clinically important therapeutics [11], we thus sought to further 
elucidate the underpinning mechanism. Three cell lines possessing distinct P-gp and BCRP phenotypes 
were employed for this purpose. 
Deconjugation of the bile acid steroid nucleus was shown to differentially modulate the cytotoxicity of 
SN-38 and CsA in a manner contrary to that anticipated based on the expression of ABCG2 (BCRP) 
and ABCB1 (P-gp). DCA, but not its tauro-conjugate, significantly reduced Caco-2 cell viability (to 
69.4 ± 2.07 %) compared to SN-38 alone (105.10 ± 1.86 %, P = 0.0002, Figure 2 (a)). Bile acid 
deconjugation did not affect the sensitivity of T84 or HT-29 cells to SN-38 (Figure 2 (b) and (c)). 
DCA was similarly determined to enhance the cytotoxicity of CsA toward the Caco-2 cell line, with 
this combination yielding a cell viability of 59.52 ± 2.71 % versus 94.88 ± 1.66 % for CsA alone (P = 
0.0004, Figure 3 (a)). CDCA was also found to augment the cytotoxicity of CsA (Figure 3 (a)). A 
reduced cell viability of 64.86 ± 2.70 % versus 94.88 ± 1.66 % was observed following dual treatment 
compared to CsA treatment alone (P = 0.0007, Figure 3 (a)). Again, these observations could not be 
explained by bile acid-induced changes to Caco-2 ABCB1 (P-gp) mRNA transcripts. Glycine 
conjugated bile salts behaved similarly to taurine conjugates (Figure 3, Supporting Information). These 
findings were further confirmed in the T84 cell line (Figure 3 (b)), which is also P-gp positive. The HT-
29 cell line, which is known to be P-gp negative [31], served as a control exhibiting no notable 
alterations to drug response (Figure 3 (c)) . 
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Figure 2. The effect of bile acid deconjugation (mediated by BSH in vivo) on Caco-2 (a), T84 (b) and HT-29 (c) 
cell viability (%) following 24 h exposure to the BCRP substrate SN-38. Unconjugated DCA was determined to 
increase the cytotoxicity of SN-38 in the Caco-2 (a) cell line, but had no impact upon the T84 (b) nor HT-29 (c) 
cell lines.  Data is presented as the mean ± SEM of 3 independent experiments performed in triplicate. 
(a) (b)
(c)
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Figure 3. The effect of bile acid deconjugation (mediated by BSH in vivo) on Caco-2 (a), T84 (b) and HT-29 (c) 
cell viability (%) following 24 h exposure to the P-gp substrate CsA. Unconjugated DCA and CDCA were 
determined to increase the cytotoxicity of CsA in the Caco-2 and T84 cell lines ((a) and (b)), but did not influence 
cytotoxicity toward the HT-29 cell line (c). Data is presented as the mean ± SEM of 4 (Caco-2) or 3 (HT-29 and 
T84) independent experiments performed in triplicate.
(a) (b)
(c)
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3.3 Impact of bile acid dehydroxylation on the cellular response to therapeutics 
The impact of microbial 7α-dehydroxylation of the cholate steroidal ring on the propensity of bile acids 
to adjust the cytotoxic action of SN-38 and CsA was simulated. Similar to the effect of deconjugation, 
bile acid dehydroxylation was associated with an increase in drug activity, illustrated by a diminution 
in cell viability following substitution of CA with DCA (Figure 4 (a)). Concurrent treatment of Caco-2 
cells with SN-38 and DCA, resulted in a cell viability of 61.56 ± 3.47 % as compared to 90.52 ± 7.8 % 
for SN-38 alone (P = 0.0147, Figure 4 (a)). The bile acid hydroxylation state did not influence SN-38 
cytotoxicity in BCRP-negative T84 (Figure 4 (b)) nor HT-29 (Figure 4 (c)) cell lines. 
DCA, but not CA, was similarly shown to enhance the cytotoxicity of CsA (43.85 ± 2.47 % following 
combination treatment as compared to 91.24 ± 14 % for CsA alone, P = 0.0157, Figure 5 (a)). This 
effect was verified in the P-gp positive T84 cell line (Figure 5 (b)); cell viability was not affected in the 
HT-29 cell line (Figure 5 (c)). Similar to the impact of deconjugation, these findings cannot be 
correlated generally to transcriptional effects on ABCB1 (P-gp) and ABCG2 (BCRP). The results 
collectively indicate that unconjugated and secondary bile acids have a greater capacity to modulate the 
uptake/activity of common efflux substrates. 
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Figure 4. The effect of bile acid dehydroxylation (mediated by 7α-dehydroxylase in vivo) on Caco-2 (a) T84 (b) 
and HT-29 (c) cell viability (%) following 24 h exposure to the BCRP substrate SN-38. The dihydroxy bile acid 
DCA was determined to increase the cytotoxicity of SN-38 in the Caco-2 cell line ((a)), but did not influence 
cytotoxicity toward the T84 nor HT-29 cell lines (c). Data is presented as the mean ± SEM of 4 (Caco-2) or 3 
(HT-29 and T84) independent experiments performed in triplicate. 
(a) (b)
(c)
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Figure 5. The effect of bile acid dehydroxylation (mediated by 7α-dehydroxylase in vivo) on Caco-2 (a), T84 (b) 
and HT-29 (c) cell viability (%) following 24 h exposure to the P-gp substrate CsA. The dihydroxy bile acid DCA 
was determined to increase the cytotoxicity of CsA in the Caco-2 and T84 cell lines ((a) and (b)), but did not 
influence cytotoxicity toward the HT-29 cell line (c). Data is presented as the mean ± SEM of 4 (Caco-2) or 3 
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In order to ascertain whether unconjugated, secondary bile acids could potentially increase SN-38 and 
CsA cytotoxicity through down-regulation of BCRP and P-gp proteins, respectively, western blotting 
was performed. No alteration to P-gp protein expression was observed in the P-gp positive cell lines 
Caco-2 and T84 (Figure 6 (a) and (b)). The HT-29 cell line was confirmed to be negative for P-gp 
protein expression (Figure 6 (a) and (c)). These mRNA and protein expression data collectively indicate 
that unconjugated and 7α-dehydroxylated bile acids modulate P-gp efflux by a mechanism distinct to 
transcription and protein translation. Similarly, regarding BCRP, no alteration to protein expression was 
noted in the BCRP-positive cell line Caco-2 (Figure 6 (a) and (c)). The T84 cell line was determined to 
be negative for BCRP hence supporting its utility as a negative control. Unconjugated DCA reduced 
BCRP protein expression relative to its conjugated counterpart in the HT-29 cell line, but this was not 






































































Figure 6. Representative western blots of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) in 
Caco-2, T84 and HT-29 cells (a). Caco-2 and T84 cells are P-gp positive, while Caco-2 and HT-29 cells are BCRP 
positive. Quantitated data from immunoblots for P-gp and BCRP are shown in (b) and (c), respectively. Cells 
were treated with TDCA, DCA or DMSO vehicle control for 24 h. Total cell lysate was harvested and subjected 
to immunoblotting with antibodies against indicated proteins. Bile acid treatments did not influence the expression 
of P-gp (b) or BCRP (c) relative to control cells. Unconjugated DCA was determined to down-regulate the 
expression of BCRP in HT-29 cells, as compared to its taurine-conjugated counterpart. Data is expressed as mean 
± SD (n = 2). 
(b) (c)
(a)
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3.4 Structure-activity relationship between bile acids and their ability to modulate the 
cellular response to a P-gp substrate
Unconjugated DCA and CDCA were shown to modulate the cytotoxicity of CsA in two P-gp positive 
cell lines (Caco-2 and T84). In an effort to investigate whether a structure-activity relationship 
underpinned bile acid-induced inhibition of P-gp functioning, simple linear regressions between the 
predicted octanol/water partition coefficient (LogP) of the test bile acids and cell viability were 
performed. Strong relationships were observed in both the Caco-2 and T84 cell lines (Figure 7), 
suggesting that the tendency of bile acids to inhibit P-gp activity is related to their hydrophobicity.








































Figure 7. The impact of bile acids on CsA-induced cytotoxicity toward the Caco-2 (a) and T84 (b) cell lines as a 
function of their octanol/water partition coefficient (predicted values were obtained using MarvinSketch version 
17.1.30.0, ChemAxon (http://www.chemaxon.com). Simple linear regression analysis was performed in 
GraphPad Prism 5.
3.5 Impact of bile acid conjugation status on rhodamine 6G uptake and bidirectional 
transport
To further examine the hypothesis that unconjugated bile acids possess a greater capacity to modulate 
the intracellular accumulation of P-gp substrates by inhibiting efflux activity, a series of uptake and 
transport studies involving a fluorescent rhodamine dye, rhodamine 6G (Rho 6G), were performed. Rho 
6G was confirmed to be a P-gp substrate by its ability to stimulate basal P-gp ATPase activity (Figure 
4, Supporting Information). 
In the Caco-2 cell line, unconjugated DCA and CDCA, but not their tauro-conjugated counterparts, 
increased the intracellular accumulation of Rho 6G following a 3 h co-incubation period at 37 °C 
(Figure 8 (a)). CsA 100 µM, used as a positive control to validate the assay, significantly increased the 
intracellular accumulation of Rho 6G (data not shown). Although not statistically significant, a similar 
trend was observed in the T84 cell line (Figure 8 (b)). The less pronounced phenotype observed in T84 
cells may reflect lower levels of P-gp expression in this cell line (Figure 6 (a)). To further prove that 
this observed enhancement in Rho 6G uptake in the presence of unconjugated bile acids was via a 
transporter-mediated, energy-dependent process, parallel experiments were performed at 4 °C and at 
room temperature (approximately 21 °C). The accumulation of Rho 6G in the absence and presence of 
test bile acids did not differ at 4 °C or 21 °C, indicating that an energy-dependent process is responsible 
for the enhancement conferred by unconjugated bile acids at 37 °C. 
(a) (b)
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Figure 8. The effect of test bile acids on Rho 6G accumulation in Caco-2 (a) and T84 (b) cells following 3 h co-
incubation. The Caco-2 37 °C experimental data illustrates that unconjugated DCA and CDCA increase the 
accumulation of Rho 6G to a greater extent than their tauro-conjugated counterparts (a). Although not significant, 
a similar trend was observed in the T84 cell line (b). A comparison of Rho 6G accumulation assays performed at 
4 °C, 21 °C and 37 °C indicates that an active transporter or carrier-mediated process is implicated. The data is 
expressed as % fluorescent dye accumulation in control cells exposed solely to Rho 6G, arbitrarily set at 100%, 
and represents the mean ± SEM of four independent experiments (n = 6 for each assay condition). 
Caco-2 monolayers are the most frequently used cellular model to simulate the intestinal epithelial 
barrier and to predict the flux of drugs across human intestinal tissue.[32] The flux of Rho 6G across 
Caco-2 monolayers in both absorptive (apical to basolateral) and secretory (basolateral to apical) 
directions was investigated in the presence of conjugated (TDCA) and deconjugated (DCA) bile acids. 
These polarized flux measurements were employed to confirm decreased P-gp efflux activity as the 
cause of the increase in Rho 6G accumulation following concurrent treatment with unconjugated bile 
acids. 
Involvement of P-gp-mediated efflux is signified by a transport ratio of greater than 2,[33] essentially 
indicating that the net flux of the drug in vivo would be towards the gastrointestinal, as opposed to the 
serosal, side. The transport ratio of Rho 6G was determined to be 16.20 ± 1.39 (Figure 9), confirming 
that it is subject to efflux in the Caco-2 monolayer model. Verapamil was used as a positive control, 
and significantly reduced the basolateral to apical permeability of Rho 6G and consequently its transport 
ratio (2.17 ± 0.29) across the Caco-2 monolayers (Figure 9) by competitively saturating the pump. 
Following a pre-incubation period of 1 h and further continuous exposure for 3 h, DCA, but not TDCA, 
significantly reduced the secretory transport of Rho 6G (P < 0.05). This alteration in apparent 
permeability significantly impacted upon the transport ratio of Rho 6G, indicating an inhibition of efflux 
activity (Figure 9).
The addition of TDCA and DCA to the apical and basolateral compartments of the transwell setup was 
associated with a reduction in TEER (Table 3, Supporting Information). This observation is not 
unexpected. Araki et al. demonstrated that micromolar concentrations of bile acids decreased the TEER 
of Caco-2 monolayers, but that this was not a consequence of permanent cellular insult.[34] Similarly 
in this study, Caco-2 monolayer viability was not affected by the presence TDCA or DCA (Figure 5, 
Supporting Information). Considering that Rho 6G is a lipophilic dye and that TDCA and DCA induced 
(a) (b)
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comparable reductions in TEER, we do not anticipate significant or differential impacts upon flux 
through the paracellular route.
















































2.01 ± 0.06 1.75 ± 0.06* (*) 8.47 ± 0.51
Figure 9. Transport ratios (PappB→A/PappA→B) of Rho 6G (5 µM) across Caco-2 monolayers in the absence and 
presence of P-gp modulators (100 µM test bile acids TDCA or DCA). Statistical significance in apparent 
permeability was assessed relative to control cells exposed to Rho 6G only (P < 0.05). (*) indicates a statistically 
significant difference between bile acid treatments (P < 0.05). Data is expressed as the mean ± SD of 2 independent 
experiments performed in triplicate. Data represents the mean ± SD of 2 independent experiments performed in 
triplicate.
3.6 Exploring the mechanism by which bile acids inhibit P-glycoprotein functioning 
P-gp functions as an ATP-dependent drug efflux pump. Compounds that interact with P-gp can be 
classified as either substrates or inhibitors according to their tendency to stimulate or inhibit the ATPase 
activity of the transporter (i.e. its ability to hydrolyse ATP), respectively. In order to elucidate the 
possible mechanisms underpinning the observed enhancement in CsA toxicity and accumulation of Rho 
6G in the presence of unconjugated bile acids, the effect of the test bile acids on P-gp ATPase activity 
was assessed using artificial human P-gp membrane vesicles. 
In general, both conjugated and deconjugated bile acids inhibited basal P-gp ATPase activity (Figure 
10 (a)). The test bile acids were also shown to inhibit substrate (verapamil or Rho 6G) stimulated P-gp 
ATPase, though this was not a generalizable effect (Figure 10 (b) and (c)).
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The effects of test bile acids at a 5 µM concentration were also examined as it is unclear what percentage 
of the treated bile acid concentration (100 µM) is available to interact with P-gp in the cellular system. 






































































































































Figure 10. The effect of 100 µM bile acids on (a) basal P-gp ATPase activity, (b) 200 µM verapamil-stimulated 
and (c) 5 µM Rho 6G-stimulated P-gp ATPase activity. RLU = relative light units. Horizontal bars are indicative 
of a statistically significant difference between conjugated and unconjugated bile acids (n = 3, mean ± SD). 
(a) (b)
(c)
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4.1 The effect of bile acid conjugation and hydroxylation status on the expression of genes 
encoding drug transporters 
Several recent studies have sought to investigate the role of the gut microbiome in influencing the 
expression of intestinal drug transporters. [35, 36] Previous studies within our research group involving 
germ-free and conventionalized mice, possessing distinct bile acid profiles, identified altered 
transcription of intestinal transporters involved in lipid transport.[9] Reanalysis of this data set (for the 
purpose of this study) additionally revealed altered transcription of enterocytic transporters involved in 
drug translocation (Figure 1 (a) and (b), Supporting Information). To the best of our knowledge, the 
effect of microbe-mediated bile acid transformations on the expression of human intestinal drug 
transporters has not been elucidated to date. 
A panel of three human intestinal cell lines were employed to examine the effects of individual bile 
acids on the transcriptional expression of drug transporters. As the disposition of both endogenous 
molecules, such as bile acids, and drugs is most often related to two superfamilies, the ABC and SLC 
transporters, we focussed our efforts on elucidating the effect of bile acid transformations on the 
transcription and activity of several clinically relevant members (Figure 1, Supporting Information). In 
general, bile acid deconjugation and dehydroxylation were associated with transcriptional upregulation 
of genes encoding these transporters (in concurrence with in-house murine data). It appears that an 
unconjugated, dihydroxy bile acid signature is fundamental to the induction of common human 
intestinal transporters as exemplified by the ability of dihydroxy CDCA and DCA, but not trihydroxy 
CA, to generally upregulate mRNA transcripts (Table 2 and 3). These findings may explain, at least 
partially, recent reports of altered drug transporter expression in dysbiotic (germ-free and antibiotic-
induced) animal models. [35] [37]
The expression of drug transporters is a major determinant of local and systemic drug exposure and 
resulting pharmacodynamic effects. Therefore, interindividual variation in drug response could be 
related to alterations in transporter expression. Taking into consideration our findings in gnotobiotic 
mice and in cultured enterocytes, we suggest that perturbation of the gut microbiota and therefore the 
bile acid pool may hence have implications for drug disposition and warrants further investigation. Such 
variation in transporter gene expression is likely to be determined by bile acid specific-stimulation of 
nuclear receptors such as FXR, PXR and the constitutive androstane receptor (CAR). In support of this, 
we report that unconjugated DCA and CDCA upregulate FGF19 (a well-known FXR-regulated gene, 
Table 2, Supporting Information) in a manner similar to that observed for ABCC2 and ABCC3, which 
are also purportedly regulated by FXR. [30] The mechanism underpinning the differential expression 
of ABCB1 (P-gp) and ABCG2 (BCRP) across the 3 cell lines following bile acid treatment, however, 
remains to be definitively elucidated. It is also challenging to decipher which of these commonly used 
cell lines provides information that is most relevant to the in vivo milieu and which would be the best 
candidate for transcriptional studies. Bourgine et al. report similar correlation coefficients between all 
3 cell lines and human small intestinal (ileal) tissue biopsies (0.672 (Caco-2), 0.708 (T84) and 0.679 
(HT-29)). The best correlation, however, was observed for human colonic tissue biopsies and T84 and 
HT-29 cell lines. [38] It is also important to note that mRNA gene expression data do not always 
correlate with the expression pattern of encoded proteins.
4.2 The effect of bile acid conjugation and hydroxylation status on the cytotoxicity of multidrug 
resistance transporter substrates
Guided by the knowledge that bile acids can significantly affect the expression of drug transporter 
mRNA in mice and in cultured human enterocytes, we investigated the possible implications for drug 
uptake using an in vitro drug cytotoxicity screen. Alterations to drug toxicity, which must succeed 
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changes to cellular accumulation, was used as a preliminary marker to assess the effect of bile acid 
treatment on the uptake and activity of a range of drugs. 
Among the bile acids tested, unconjugated dihydroxy bile acids modulated the cytotoxicity of the model 
MDR substrates SN-38 and CsA, although these effects appeared to be drug-specific. We reason that 
the transporter specificity of these substrates (BCRP[39] and P-gp[40], respectively) may explain the 
differential tendencies of unconjugated, dihydroxy bile acids to modulate their cytotoxicity (Figure 2-
5). However, such bile acid-dependent drug toxicities could not be explained by bile acid-induced 
changes to ABCG2 (BCRP) and ABCB1 (P-gp) mRNA expression (Table 2 and Table 3) nor to 
expressional changes in BCRP or P-gp proteins (Figure 6).
Cellular energy consumption constitutes one source of multidrug resistance inhibition as drug efflux is 
an energy-dependent process. Neither conjugated nor deconjugated bile acids at working concentrations 
induced any appreciable changes in cellular ATP levels (Figure 2, Supporting Information, cell viability 
based on ATP quantification). Hence, it is unlikely that a bile acid-induced depletion of intracellular 
ATP underpins the chemo-sensitization of Caco-2 and T84 cells as has been previously reported for 
non-physiological surfactants such as Pluronic P85.[41, 42] We reason that unconjugated bile acids 
must sensitize cells to SN-38 and CsA through alternative, functional effects on these transporter 
proteins.[14]
4.3 The effect of bile acid conjugation status on the cellular uptake of P-gp substrates
The P-gp activity of cell lines has been routinely investigated by monitoring the accumulation and efflux 
of small, fluorescent molecules, such as rhodamine dyes. Rho 6G is reportedly a relatively hydrophobic 
P-gp substrate, [43] which was verified herein by its capacity to stimulate basal P-gp ATPase (Figure 
2, Supporting Information). Previous studies by Zastre et al., indicate that the P-gp transporter is 
responsible for limiting the intracellular accumulation of Rho 6G in Caco-2 cells, with little or no 
contribution from multidrug resistance protein isoforms.[43] Unconjugated DCA and CDCA 
significantly increased Caco-2 cellular accumulation of Rho 6G (P < 0.05), an effect that was not 
evident in the presence of tauro-conjugated equivalents (Figure 8 (a)). Parallel studies performed at 4 
°C and 21 °C confirmed that the effect of bile acid deconjugation on the accumulation of Rho 6G is an 
energy-dependent process (Figure 8 (a)). In T84 cells, although not statistically significant, a similar 
trend was observed (Figure 8 (b)). 
This phenomenon supports the hypothesis that unconjugated bile acids can positively modulate the 
accumulation of P-gp substrates, thereby pointing to a potential role for microbial BSH in influencing 
the uptake and activity of molecules susceptible to P-gp exclusion. We note reports in non-intestinal 
cell lines, which suggest that in addition to susceptibility to P-gp efflux, Rho 6G may be subject to 
uptake by organic cation transporters (OCT1 and OCT2). [44] While the basal mRNA expression of 
SLC22A1 (encoding OCT1) in the intestinal cell lines employed in this study is low (Table 1, 
Supporting Information), the contribution of these transporters to Rho 6G may warrant further 
consideration.
4.4 The effect of bile acid conjugation status on the transport of P-gp substrates across Caco-2 
monolayers: a model of the gastrointestinal barrier
Bidirectional transport studies (with polarized Caco-2 monolayers) were employed to confirm and 
quantify the impact of bile acid deconjugation on the translocation of Rho 6G, specifically enabling 
assessment of alterations to absorptive and secretory apparent permeability. Bile acids were added to 
both the apical and basolateral compartments as bile acids are present both intraluminally and in the 
portal circulation in vivo. This experiment is the first in the literature to demonstrate that micromolar 
concentrations DCA can preferentially decrease (relative to its tauro-conjugate) the basolateral to apical 
secretion of Rho 6G and to consequentially identify a possible role for microbial BSH in modulating 
the uptake of P-gp substrates (Figure 9). Lo et al. previously demonstrated that 1.2 mM DCA reduced 
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the secretion of epirubicin, a P-gp substrate, across Caco-2 cell monolayers.[14] Lo and colleagues 
speculated that the membrane perturbation induced by DCA, and identified by Sakai et al.,[45] may 
invoke changes in the fluidity of the membrane and hence inhibit the activity of P-gp. Given the 
surfactant nature of bile acids and observed reductions in TEER (Table 3, Supporting Information), 
changes in membrane fluidity may partially underpin the ability of certain bile acids to circumvent P-
gp-mediated efflux. However, no statistically significant difference in TEER reduction was noted 
following treatment with TDCA and DCA, we hence sought to further investigate the preferential 
capacity of unconjugated DCA to attenuate the active efflux of Rho 6G.
4.5 The effect of bile acid conjugation status on P-gp ATPase activity
ABC transporters contain ATP-binding domains that possess ATPase activity, that is, the ability to 
hydrolyse ATP to ADP (adenosine diphosphate), providing the energy for substrate translocation. Many 
P-gp modulators such as verapamil and CsA, are substrates themselves, competitively inhibiting its 
functioning without interrupting the catalytic turnover of the pump.[46] Unconjugated DCA and CDCA 
were determined to modulate the cytotoxicity of CsA (Figures 3 (a-b)) and the accumulation of Rho 6G 
(Figure 8), despite neither bile acid invoking changes to basal P-gp expression (Figure 6). It was 
therefore postulated that unconjugated bile acids may be substrates for P-gp efflux or inhibitors of P-gp 
ATPase, thereby preferentially mitigating the active efflux.
Both conjugated and deconjugated bile acids were generally found to inhibit basal, as well as substrate 
(verapamil and Rho 6G) stimulated P-gp ATPase activity (Figure 10). This inability of the P-gp-Glo 
assay system to identify a role for bile acid conjugation status in differentially modulating P-gp ATPase 
activity most likely reflects the artificial nature of the membrane vesicles. Physiological membranes are 
relatively impermeable to ionized (conjugated) bile salt species,[47] and hence their transport is 
dependent upon carrier proteins. In contrast, a significant proportion of unconjugated bile acids exist in 
the unionized form at intestinal pH and are consequently available for passive, non-ionic diffusion. In 
general, the unionized form of a weak acid will permeate the intestinal membrane much quicker than 
its ionized form.[48] In a cellular model, the cytosolic leaflet of the plasma membrane, which contains 
the substrate binding site and two nucleotide binding domains, must be approached by the passive 
diffusion of a molecule across the lipid bilayer, whereas in a cell membrane fraction (such as the P-gp-
Glo system) it is directly accessible from aqueous phase.[49] We propose that in the cellular system 
unconjugated bile acids, such as DCA and CDCA, are thus most likely to interact with P-gp due to an 
elevated hydrophobic character. To the best of our knowledge, this is the first study to report the ability 
of bile acids to modulate P-gp activity through an inhibition of P-gp ATPase. Telbisz et al. have, 
however, demonstrated that glycocholic acid (GCA), taurocholic acid (TCA) and CA can significantly 
reduce basal BCRP (ABCG2) ATPase activity.[50] Whilst the bile acids included in our study were not 
considered by Telbisz et al., we suggest that the differential inhibition of BCRP ATPase by DCA, as 
compared to TDCA, may perhaps partially explain the increased cytotoxicity of the BCRP (ABCG2) 
substrate SN-38 (Figure 2 (a)) and warrants further investigation. Overall, the possibility that bile acids 
may compete with P-gp substrates for competitive extrusion via the active site was excluded due to 
their tendency to inhibit, rather than stimulate, basal P-gp ATPase.
While our findings consistently indicate that unconjugated bile acids preferentially modulate the 
uptake/activity of specific P-gp and BCRP transporter substrates in vitro, the contribution of other 
transport processes (additional active transporters or indeed passive diffusion mechanisms) cannot be 
ruled out entirely. In interpreting these findings, it is important to be cognizant that many drug 
transporter proteins exhibit significant overlap in substrate specificity. [51]
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In concurrence with in-house observations of altered intestinal transporter mRNA transcripts in germ-
free and conventionalized mice, we demonstrated that unconjugated/dihydroxy bile acids can similarly 
alter the expression of genes encoding human drug transporters in vitro. Future work should be directed 
toward investigating possible implications for drug disposition in vivo.
This study has identified that the conjugation and hydroxylation status of a bile acid dictates its capacity 
to modulate the uptake of efflux transporter substrates and thereby circumvent multidrug resistance in 
vitro. This study has hence indirectly identified a role for microbial bile acid metabolism in modulating 
MDR transporters, which in the case of P-gp appears to be mediated by inhibition of ATPase activity. 
The generalizable attenuating effect of deconjugation on P-gp functionality can be attributed to the more 
favourable physicochemical property of nonionization, pointing to a structure-activity relationship 
between the bile acid steroid nucleus and reversal of multidrug resistance. 
While future work is necessary to decipher whether this phenomenon could persist in the more complex 
in vivo milieu in presence of fat-soluble vitamins and lipophilic xenobiotics; this study provides 
additional impetus to consider microbial metabolites, in addition to the host, as possible factors 
influencing drug pharmacokinetics. Perturbation of the human gut microbiota, and consequently the 
bile acid metabolome[52], could contribute to altered drug uptake across the intestinal barrier and 
therefore potentially constitute a source of pharmacokinetic variability. 
Supporting Information
Supporting information is available as additional figures and tables as noted in the text. Schematic 
indicating polarized expression of common intestinal drug transporter proteins; cell viability data 
outlining selection of non-cytotoxic, working concentrations of bile acids; average cycle threshold 
values of drug transporter genes considered in this study relative to β-actin; cell viability data 
investigating the impact of glycine-deconjugation on the ability of bile acids to circumvent multidrug 
resistance; P-gp Glo assay data of Rho 6G; TEER of Caco-2 monolayers; cell viability of Caco-2 
monolayers; P-gp Glo assay data of 5 µM bile acids.
Acknowledgements 
Elaine F. Enright is a recipient of a Government of Ireland Postgraduate Scholarship from the Irish 
Research Council (grant number GOIPG/2015/3261). The authors acknowledge the funding of APC 
Microbiome Ireland by the Science Foundation of Ireland Centres for Science, Engineering and 
Technology (CSET) programme (Grant Number SFI/12/RC/2273). The authors wish to kindly 
acknowledge the expertise and support of Dr. Maria Angeles Nuñez Sanchez with western blotting. 
Page 28 of 31
































































[1]. Enright, E. F.; Gahan, C. G.; Joyce, S. A.; Griffin, B. T.  The impact of the gut microbiota on 
drug metabolism and clinical outcome. The Yale journal of biology and medicine 2016, 89, (3), 375-
382.
[2]. Enright, E. F.; Joyce, S. A.; Gahan, C. G.; Griffin, B. T.  Impact of gut microbiota-mediated 
bile acid metabolism on the solubilization capacity of bile salt micelles and drug solubility. Mol Pharm 
2017, 14, (4), 1251-1263.
[3]. Mukaizawa, F.; Taniguchi, K.; Miyake, M.; Ogawara, K.-i.; Odomi, M.; Higaki, K.; Kimura, 
T.  Novel oral absorption system containing polyamines and bile salts enhances drug transport via both 
transcellular and paracellular pathways across Caco-2 cell monolayers. International Journal of 
Pharmaceutics 2009, 367, (1), 103-108.
[4]. Meaney, C. M.; O'Driscoll, C. M.  A comparison of the permeation enhancement potential of 
simple bile salt and mixed bile salt:fatty acid micellar systems using the CaCo-2 cell culture model. 
International Journal of Pharmaceutics 2000, 207, (1), 21-30.
[5]. Chiang, J. Y.  Bile acid regulation of gene expression: roles of nuclear hormone receptors. 
Endocrine reviews 2002, 23, (4), 443-63.
[6]. Begley, M.; Gahan, C. G.; Hill, C.  The interaction between bacteria and bile. FEMS 
microbiology reviews 2005, 29, (4), 625-51.
[7]. Teng, S.; Piquette-Miller, M.  Regulation of Transporters by Nuclear Hormone Receptors: 
Implications during Inflammation. Molecular Pharmaceutics 2008, 5, (1), 67-76.
[8]. Long, S. L.; Gahan, C. G. M.; Joyce, S. A.  Interactions between gut bacteria and bile in health 
and disease. Molecular Aspects of Medicine 2017, 56, (Supplement C), 54-65.
[9]. Joyce, S. A.; MacSharry, J.; Casey, P. G.; Kinsella, M.; Murphy, E. F.; Shanahan, F.; Hill, C.; 
Gahan, C. G. M.  Regulation of host weight gain and lipid metabolism by bacterial bile acid 
modification in the gut. Proceedings of the National Academy of Sciences of the United States of 
America 2014, 111, (20), 7421-7426.
[10]. Sayin, Sama I.; Wahlström, A.; Felin, J.; Jäntti, S.; Marschall, H.-U.; Bamberg, K.; Angelin, 
B.; Hyötyläinen, T.; Orešič, M.; Bäckhed, F.  Gut microbiota regulates bile acid metabolism by reducing 
the levels of tauro-beta-muricholic acid, a naturally occurring fxr antagonist. Cell Metabolism 2013, 17, 
(2), 225-235.
[11]. Estudante, M.; Morais, J. G.; Soveral, G.; Benet, L. Z.  Intestinal drug transporters: An 
overview. Advanced Drug Delivery Reviews 2013, 65, (10), 1340-1356.
[12]. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M.  Targeting 
multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5, (3), 219-234.
[13]. Makhey, V. D.; Guo, A.; Norris, D. A.; Hu, P.; Yan, J.; Sinko, P. J.  Characterization of the 
regional intestinal kinetics of drug efflux in rat and human intestine and in caco-2 cells. Pharmaceutical 
Research 1998, 15, (8), 1160-1167.
[14]. Lo, Y.-L.; Huang, J.-D.  Effects of sodium deoxycholate and sodium caprate on the transport 
of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochemical 
Pharmacology 2000, 59, (6), 665-672.
[15]. Germann, U. A.  P-glycoprotein—a mediator of multidrug resistance in tumour cells. European 
Journal of Cancer 1996, 32, (6), 927-944.
[16]. O'Brien, F. E.; O'Connor, R. M.; Clarke, G.; Dinan, T. G.; Griffin, B. T.; Cryan, J. F.  P-
glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram 
in rodents. Neuropsychopharmacology 2013, 38, (11), 2209-2219.
[17]. Albring, A.; Wendt, L.; Harz, N.; Engler, H.; Wilde, B.; Kribben, A.; Lindemann, M.; 
Schedlowski, M.; Witzke, O.  Relationship between pharmacokinetics and pharmacodynamics of 
calcineurin inhibitors in renal transplant patients. Clinical transplantation 2015, 29, (4), 294-300.
[18]. Wu, C.-Y.; Benet, L. Z.; Hebert, M. F.; Gupta, S. K.; Rowland, M.; Gomez, D. Y.; Wacher, V. 
J.  Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with 
cyclosporine. Clinical Pharmacology & Therapeutics 1995, 58, (5), 492-497.
Page 29 of 31































































[19]. Masuda, S.; Goto, M.; Kiuchi, T.; Uemoto, S.; Kodawara, T.; Saito, H.; Tanaka, K.; Inui, K.-i.  
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient 
of living donor liver transplantation. Liver Transplantation 2003, 9, (10), 1108-1113.
[20]. Lown, K. S.; Mayo, R. R.; Leichtman, A. B.; Hsiao, H.-l.; Turgeon, D. K.; Schmiedlin-Ren, P.; 
Brown, M. B.; Guo, W.; Rossi, S. J.; Benet, L. Z.; Watkins, P. B.  Role of intestinal P-glycoprotein 
(mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical Pharmacology & 
Therapeutics 1997, 62, (3), 248-260.
[21]. Masuo, T.; Okamura, S.; Zhang, Y.; Mori, M.  Cyclosporine A inhibits colorectal cancer 
proliferation probably by regulating expression levels of c-Myc, p21WAF1/CIP1 and proliferating cell 
nuclear antigen. Cancer Letters 2009, 285, (1), 66-72.
[22]. Mao, Q.; Unadkat, J. D.  Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug 
Transport—an Update. The AAPS Journal 2015, 17, (1), 65-82.
[23]. Dudeja, P. K.; Anderson, K. M.; Harris, J. S.; Buckingham, L.; Coon, J. S.  Reversal of 
multidrug-resistance phenotype by surfactants: Relationship to membrane lipid fluidity. Archives of 
Biochemistry and Biophysics 1995, 319, (1), 309-315.
[24]. Lozupone, C. A.; Stombaugh, J. I.; Gordon, J. I.; Jansson, J. K.; Knight, R.  Diversity, stability 
and resilience of the human gut microbiota. Nature 2012, 489, (7415), 220-230.
[25]. Livak, K. J.; Schmittgen, T. D.  Analysis of relative gene expression data using real-time 
quantitative pcr and the 2(-delta delta c(t)) method. Methods (San Diego, Calif.) 2001, 25, (4), 402-8.
[26]. de Aguiar Vallim, Thomas Q.; Tarling, Elizabeth J.; Edwards, Peter A.  Pleiotropic roles of bile 
acids in metabolism. Cell Metabolism 2013, 17, (5), 657-669.
[27]. Chewchuk, S.; Boorman, T.; Edwardson, D.; Parissenti, A. M.  Bile acids increase doxorubicin 
sensitivity in abcc1-expressing tumour cells. Scientific Reports 2018, 8, (1), 5413.
[28]. Inokuchi, A.; Hinoshita, E.; Iwamoto, Y.; Kohno, K.; Kuwano, M.; Uchiumi, T.  Enhanced 
expression of the human multidrug resistance protein 3 by bile salt in human enterocytes. A 
transcriptional control of a plausible bile acid transporter. The Journal of biological chemistry 2001, 
276, (50), 46822-9.
[29]. Kok, T. M. C. M. D.; Van Faassen, A.; Glinghammar, B.; Pachen, D. M. F. A.; Rafter, J. J.; 
Baeten, C. G. M. I.; Engels, L. G. J. B.; Kleinjans, J. C. S.  Bile acid concentrations, cytotoxicity, and 
ph of fecal water from patients with colorectal adenomas. Digestive Diseases and Sciences 1999, 44, 
(11), 2218-2225.
[30]. Staudinger, J. L.; Woody, S.; Sun, M.; Cui, W.  Nuclear-receptor-mediated regulation of drug- 
and bile-acid-transporter proteins in gut and liver. Drug metabolism reviews 2013, 45, (1), 48-59.
[31]. Schumacher, U.; Nehmann, N.; Adam, E.; Mukthar, D.; Slotki, I. N.; Horny, H.-P.; Flens, M. 
J.; Schlegelberger, B.; Steinemann, D.  MDR-1-overexpression in HT 29 colon cancer cells grown in 
SCID mice. Acta Histochemica 2012, 114, (6), 594-602.
[32]. Artursson, P.; Palm, K.; Luthman, K.  Caco-2 monolayers in experimental and theoretical 
predictions of drug transport. Advanced Drug Delivery Reviews 1996, 22, (1), 67-84.
[33]. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-
Singh, C. S.  Rational use of in vitro p-glycoprotein assays in drug discovery. Journal of Pharmacology 
and Experimental Therapeutics 2001, 299, (2), 620.
[34]. Araki, Y.; Katoh, T.; Ogawa, A.; Bamba, S.; Andoh, A.; Koyama, S.; Fujiyama, Y.; Bamba, T.  
Bile acid modulates transepithelial permeability via the generation of reactive oxygen species in the 
Caco-2 cell line. Free Radical Biology and Medicine 2005, 39, (6), 769-780.
[35]. Kuno, T.; Hirayama-Kurogi, M.; Ito, S.; Ohtsuki, S.  Effect of intestinal flora on protein 
expression of drug-metabolizing enzymes and transporters in the liver and kidney of germ-free and 
antibiotics-treated mice. Molecular Pharmaceutics 2016, 13, (8), 2691-2701.
[36]. Fu, Z. D.; Selwyn, F. P.; Cui, J. Y.; Klaassen, C. D.  RNA-seq profiling of intestinal expression 
of xenobiotic processing genes in germ-free mice. Drug Metabolism and Disposition 2017, 45, (12), 
1225.
[37]. Zhang, Y.; Limaye, P. B.; Renaud, H. J.; Klaassen, C. D.  Effect of various antibiotics on 
modulation of intestinal microbiota and bile acid profile in mice. Toxicology and Applied Pharmacology 
2014, 277, (2), 138-145.
[38]. Bourgine, J.; Billaut-Laden, I.; Happillon, M.; Lo-Guidice, J. M.; Maunoury, V.; Imbenotte, 
M.; Broly, F.  Gene expression profiling of systems involved in the metabolism and the disposition of 
Page 30 of 31































































xenobiotics: comparison between human intestinal biopsy samples and colon cell lines. Drug 
metabolism and disposition: the biological fate of chemicals 2012, 40, (4), 694-705.
[39]. Nakatomi, K.; Yoshikawa, M.; Oka, M.; Ikegami, Y.; Hayasaka, S.; Sano, K.; Shiozawa, K.; 
Kawabata, S.; Soda, H.; Ishikawa, T.; Tanabe, S.; Kohno, S.  Transport of 7-Ethyl-10-
hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. 
Biochemical and Biophysical Research Communications 2001, 288, (4), 827-832.
[40]. Silva, R.; Vilas-Boas, V.; Carmo, H.; Dinis-Oliveira, R. J.; Carvalho, F.; de Lourdes Bastos, 
M.; Remião, F.  Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic 
strategy. Pharmacology & Therapeutics 2015, 149, (Supplement C), 1-123.
[41]. Batrakova, E. V.; Li, S.; Alakhov, V. Y.; Elmquist, W. F.; Miller, D. W.; Kabanov, A. V.  
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic p85. Pharmaceutical 
Research 2003, 20, (10), 1581-1590.
[42]. Kabanov, A. V.; Batrakova, E. V.; Yu. Alakhov, V.  An essential relationship between ATP 
depletion and chemosensitizing activity of Pluronic® block copolymers. Journal of Controlled Release 
2003, 91, (1), 75-83.
[43]. Zastre, J. A.; Jackson, J. K.; Wong, W.; Burt, H. M.  P-Glycoprotein Efflux Inhibition by 
Amphiphilic Diblock Copolymers: Relationship between Copolymer Concentration and Substrate 
Hydrophobicity. Molecular Pharmaceutics 2008, 5, (4), 643-653.
[44]. Ugwu, M. C.; Oli, A.; Esimone, C. O.; Agu, R. U.  Organic cation rhodamines for screening 
organic cation transporters in early stages of drug development. Journal of Pharmacological and 
Toxicological Methods 2016, 82, 9-19.
[45]. Sakai, M.; Imai, T.; Ohtake, H.; Azuma, H.; Otagiri, M.  Effects of absorption enhancers on the 
transport of model compounds in caco-2 cell monolayers: Assessment by confocal laser scanning 
microscopy. Journal of Pharmaceutical Sciences 1997, 86, (7), 779-785.
[46]. Maki, N.; Hafkemeyer, P.; Dey, S.  Allosteric modulation of human p-glycoprotein: Inhibition 
of transport by preventing substrate translocation and dissociation. Journal of Biological Chemistry 
2003, 278, (20), 18132-18139.
[47]. Dietschy, J. M.  Mechanisms for the intestinal absorption of bile acids. Journal of Lipid 
Research 1968, 9, (3), 297-309.
[48]. Schanker, L. S.; Tocco, D. J.; Brodie, B. B.; Hogben, C. A. M.  Absorption of drugs from the 
rat small intestine. Journal of Pharmacology and Experimental Therapeutics 1958, 123, (1), 81.
[49]. Nervi, P.; Li-Blatter, X.; Aanismaa, P.; Seelig, A.  P-glycoprotein substrate transport assessed 
by comparing cellular and vesicular ATPase activity. Biochimica et biophysica acta 2010, 1798, (3), 
515-25.
[50]. Telbisz, Á.; Özvegy-Laczka, C.; Hegedűs, T.; Váradi, A.; Sarkadi, B.  Effects of the lipid 
environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 
protein. Biochemical Journal 2013, 450, (2), 387.
[51]. Schinkel, A. H.; Jonker, J. W.  Mammalian drug efflux transporters of the ATP binding cassette 
(ABC) family: an overview. Adv Drug Deliv Rev 2003, 55, (1), 3-29.
[52]. Enright, E. F.; Griffin, B. T.; Gahan, C. G. M.; Joyce, S. A.  Microbiome-mediated bile acid 
modification: Role in intestinal drug absorption and metabolism. Pharmacological research 2018, 133, 
170-186.
 
Page 31 of 31
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
